January 27, 2026
Finance

Wall Street Analysts Revise Price Targets for Key Stocks Including Baker Hughes

Updated forecasts indicate potential rallies and cautions across multiple sectors ahead of Tuesday trading

Loading...
Loading quote...

Summary

Several prominent Wall Street analysts have recently adjusted their price targets and ratings for a range of notable companies, including Baker Hughes, Acumen Pharmaceuticals, and Exelixis, among others. These changes reflect shifts in market expectations ahead of upcoming trading sessions and provide insight into the analysts' outlooks on stock performance based on current valuations and sector dynamics.

Key Points

BMO Capital raised Baker Hughes price target to $65, maintaining Outperform rating.
BTIG increased Acumen Pharmaceuticals target to $7 with continued Buy rating.
Brown & Brown and W. R. Berkley ratings remain Neutral amidst price target cuts.
Deutsche Bank upgraded CoreWeave from Hold to Buy and raised price target to $140.

Wall Street analysts have issued new evaluations and price targets for a variety of companies, signaling meaningful shifts in their investment outlooks as the market prepares for Tuesday’s session. Among the stocks seeing notable changes is Baker Hughes Company (NASDAQ:BKR), where BMO Capital increased the price target from $55 to $65, accompanied by an Outperform rating maintained by analyst Phillip Jungwirth. Baker Hughes shares concluded Monday’s trading at $56.29, reflecting a slightly positive market sentiment.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) experienced a significant price target hike by BTIG. The firm raised its target from $4 to $7, holding onto its Buy rating as analyst Thomas Shrader continues to support the stock. The pharmaceutical company’s shares closed at $2.08 on Monday, indicating potential upside from the revised projections.

Exelixis, Inc. (NASDAQ:EXEL) also saw an upward revision, with HC Wainwright & Co. increasing its price target from $49 to $52. Robert Burns, the overseeing analyst, preserved the Buy rating amidst a closing price of $43.61, implying optimistic expectations for the biotech firm.

Conversely, some revisions indicate more cautious stances. Brown & Brown, Inc. (NYSE:BRO) had its price target reduced from $94 to $90 by B of A Securities, maintaining a Neutral rating under analyst Joshua Shanker. Shares ended Monday at $79.62, signaling tempered enthusiasm for the insurance company’s near-term prospects.

Similarly, W. R. Berkley Corporation (NYSE:WRB) saw Mizuho lower its price target slightly from $69 to $67, while retaining a Neutral rating assigned by analyst Yaron Kinar. The stock closed at $66.88, suggesting limited expected growth within its sector.

In other adjustments, Jones Trading brought Dynex Capital, Inc. (NYSE:DX) price target up from $14 to $15.25, maintaining a Buy rating as analyst Jason Weaver continues endorsing the stock, which closed Monday at $14.60.

Scotiabank reduced its price target for Datadog, Inc. (NASDAQ:DDOG) from $217 to $180. Analyst Patrick Colville kept a Sector Outperform rating despite share prices closing at $136.64, reflecting a substantial valuation gap relative to expectations.

On the rare earth front, Canaccord Genuity increased USA Rare Earth, Inc. (NASDAQ:USAR)'s target to $33 from $23, supporting a Buy rating per analyst George Gianarikas. The shares ended Monday at $26.72, suggesting room for price appreciation based on recent analyses.

CoreWeave, Inc. (NASDAQ:CRWV) experienced a bullish upgrade from Deutsche Bank, with Brad Zelnick raising the price target from $100 to $140, accompanied by an upgrade from Hold to Buy. The stock closed at $98.31, just below previous guidance levels.

Lastly, Morgan Stanley lowered its price target for Clearwater Analytics Holdings, Inc. (NYSE:CWAN) from $27 to $24.55 and downgraded the stock from Overweight to Equal-Weight, reflecting increased caution. James Faucette, the analyst responsible, observed the stock closing at $24.13, closely aligning with the revised target.

The diversity in analyst revisions, ranging from upgrades to downgrades, emphasizes the varying perspectives on company fundamentals and market conditions. While some firms project strong growth trajectories and opportunity, others advise restraint, highlighting uncertainties ahead.


Key Points:

  • BMO Capital increased Baker Hughes’ price target to $65, maintaining an Outperform rating.
  • BTIG doubled down on Acumen Pharmaceuticals with a price target boost to $7 and a Buy rating.
  • Several companies, including Brown & Brown and W. R. Berkley, saw reduced price targets coupled with Neutral ratings.
  • CoreWeave received a notable upgrade from Deutsche Bank, reflecting heightened confidence.

Risks and Uncertainties:

  • Price target reductions for some firms suggest caution due to possible market headwinds or company-specific challenges.
  • Downgrades such as Clearwater Analytics’ indicate potential volatility or reevaluation of growth prospects.
  • The spread between current prices and increased targets may reflect market uncertainty regarding realization of growth forecasts.
  • Ratings like Sector Outperform with significant price target cuts underscore the unpredictability within certain sectors.
Risks
  • Price target reductions indicate market caution for some companies.
  • Downgrades reflect uncertainty about near-term growth for firms like Clearwater Analytics.
  • Significant gaps between current prices and price targets suggest potential volatility.
  • Sector rating adjustments reveal unpredictable market conditions in technology and financial sectors.
Disclosure
Education only / not financial advice
Search Articles
Category
Finance

Financial News

Ticker Sentiment
BKR - positive
Related Articles
Significant Declines in Dogecoin and Shiba Inu Prompt Technical Analysis on Key Support Levels

Dogecoin and Shiba Inu experienced notable price drops recently, with both cryptocurrencies losing g...

Becton Dickinson Faces Market Headwinds Amid Transition and Revised Earnings Projections

Becton Dickinson & Co. posted first-quarter earnings above analyst expectations but trimmed its fisc...

Aramark Stock Rises Following Better-Than-Expected Quarterly Results and Positive Business Outlook

Shares of Aramark (NYSE: ARMK) advanced notably after the company reported first-quarter earnings th...

Interactive Brokers Broadens Crypto Trading with New Coinbase Derivatives Launch

Interactive Brokers has introduced new nano-sized Bitcoin and Ethereum futures through a partnership...

Alphabet Initiates $20 Billion Bond Offering as Shares Experience Downturn

Alphabet Inc., the parent company of Google, has announced plans to issue $20 billion in bonds acros...

Ford Anticipates Q4 Earnings Amid Signs of Operational Strength and Mixed Market Signals

Ford Motor Company is preparing to release its fourth-quarter earnings report with expectations set ...